*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Zafgen, Inc., is a clinical-stage biopharmaceutical company. The Company uses its proprietary methionine aminopeptidase 2 (MetAP2) biology platform to develop novel therapies for patients affected by complex metabolic diseases. Its product candidate is ZGN-1061 which is a novel fumagillin-class MetAP2 inhibitor that is used to treat type 2 diabetes and other related metabolic disorders. Type 2 diabetes is a prevalent, chronic, progressive and multifactorial disorder that leads to increased microvascular and macrovascular disease and as such increases risk of death from cardiovascular disease, stroke, and kidney failure. Its MetAP2 development candidate ZGN-1258 is administered by subcutaneous injection. ZGN-1258 is used for the treatment of Prader-Willi syndrome (PWS). PWS is a rare and complex genetic disorder characterized by physiologic, cognitive and behavioral symptoms including hyperphagia, uncontrollable hunger and its related behaviors, and obesity.
Market Cap:43.4M; Shares Outstanding:37.4M; Q3 2019(9/30/19): Cash 82.01M. Loss 12.92M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 83，no change
Shares hold: 23110.7k shares. no change
shares% hold: 61.84%，no change